• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬兰人群中糖尿病性黄斑水肿和增殖性糖尿病视网膜病变的发病率、患病率、进展为视力损害的情况及其玻璃体内治疗模式。

The incidence and prevalence of diabetic macular edema and proliferative diabetic retinopathy, their progression to visual impairment and patterns in their intravitreal treatment in the Finnish population.

作者信息

Heloterä Hanna, Arffman Martti, Sund Reijo, Keskimäki Ilmo, Kaarniranta Kai

机构信息

Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland.

Roche Oy, Espoo, Finland.

出版信息

Acta Ophthalmol. 2024 Sep;102(6):643-652. doi: 10.1111/aos.16675. Epub 2024 Mar 24.

DOI:10.1111/aos.16675
PMID:38523129
Abstract

PURPOSE

The worldwide prevalence of diabetes mellitus (DM) continues to increase. As DM is linked to various ophthalmological comorbidities, it is crucial to understand the incidence and the treatment patterns of these complications to minimise the treatment burden for the patient and the healthcare system. This study aims to evaluate the incidence and prevalence of diabetic macular oedema (DME) and proliferative diabetic retinopathy (PDR) and to analyse intravitreal (IVT) treatment patterns and responses in the Finnish population with diabetes.

METHODS

A nationwide data register containing details of over 20-year-old individuals with diabetes was used in the analyses.

RESULTS

The incidence and prevalence of DME and PDR among the Finnish population with diabetes either declined or remained stable during 2007-2017 (Incidence rate: DME -40.8%, PDR -65.3%; prevalence rate: DME +4.7%, PDR -11.2%). During the same period, number of persons suffering from diabetes increased by +58.3%. The total number of IVT injections increased by 261.7%; the number of patients receiving IVT treatments increased by 133.6% from 2011 to 2017, reflecting changes in patient numbers in the ophthalmology departments. Furthermore, irrespective of the rising number of patients with diabetes, the numbers with visual impairment declined by 75.8% among DME and by 75.7% among PDR patients in 2007-2017.

CONCLUSIONS

Regardless of the considerable increase in the workload of ophthalmology departments, the healthcare system has been able to reduce both the age and sex standardised incidence of DME and PDR among the diabetic population suffering from a visual impairment associated with this disease.

摘要

目的

全球糖尿病(DM)患病率持续上升。由于糖尿病与多种眼科合并症相关,了解这些并发症的发病率和治疗模式对于减轻患者和医疗系统的治疗负担至关重要。本研究旨在评估糖尿病性黄斑水肿(DME)和增殖性糖尿病视网膜病变(PDR)的发病率和患病率,并分析芬兰糖尿病患者群体的玻璃体内(IVT)治疗模式及反应。

方法

分析中使用了一个包含20岁以上糖尿病患者详细信息的全国性数据登记册。

结果

2007 - 2017年期间,芬兰糖尿病患者群体中DME和PDR的发病率和患病率要么下降,要么保持稳定(发病率:DME下降40.8%,PDR下降65.3%;患病率:DME上升4.7%,PDR下降11.2%)。同一时期,糖尿病患者人数增加了58.3%。IVT注射总数增加了261.7%;2011年至2017年接受IVT治疗的患者人数增加了133.6%,反映了眼科部门患者数量的变化。此外,尽管糖尿病患者数量不断增加,但在2007 - 2017年期间,DME患者中视力受损人数下降了75.8%,PDR患者中下降了75.7%。

结论

尽管眼科部门的工作量大幅增加,但医疗系统已能够降低患有与该疾病相关视力损害的糖尿病患者群体中DME和PDR的年龄和性别标准化发病率。

相似文献

1
The incidence and prevalence of diabetic macular edema and proliferative diabetic retinopathy, their progression to visual impairment and patterns in their intravitreal treatment in the Finnish population.芬兰人群中糖尿病性黄斑水肿和增殖性糖尿病视网膜病变的发病率、患病率、进展为视力损害的情况及其玻璃体内治疗模式。
Acta Ophthalmol. 2024 Sep;102(6):643-652. doi: 10.1111/aos.16675. Epub 2024 Mar 24.
2
Gender-related differences in patients treated with intravitreal anti-vascular endothelial growth factor medication for diabetic macular oedema.性别对接受玻璃体内抗血管内皮生长因子药物治疗糖尿病黄斑水肿患者的影响。
Eur J Ophthalmol. 2020 Nov;30(6):1410-1417. doi: 10.1177/1120672119899627. Epub 2020 Jan 14.
3
Long-term Treatment Patterns for Diabetic Macular Edema: Up to 6-Year Follow-up in the IRIS® Registry.糖尿病性黄斑水肿的长期治疗模式:IRIS® 注册研究长达 6 年的随访结果。
Ophthalmol Retina. 2024 Nov;8(11):1074-1082. doi: 10.1016/j.oret.2024.05.017. Epub 2024 Jun 1.
4
The Effect of Delay in Care among Patients Requiring Intravitreal Injections.需要玻璃体腔内注射的患者延迟治疗的影响。
Ophthalmol Retina. 2021 Oct;5(10):975-980. doi: 10.1016/j.oret.2020.12.020. Epub 2021 Jan 1.
5
The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.RELATION 研究:雷珠单抗联合激光光凝治疗与单纯激光治疗对 NPDR 和 PDR 合并糖尿病黄斑水肿患者的疗效和安全性。
Acta Ophthalmol. 2018 May;96(3):e377-e385. doi: 10.1111/aos.13574. Epub 2017 Nov 1.
6
Real-life experience of ranibizumab for diabetic macular edema in Taiwan.台湾地区雷珠单抗治疗糖尿病性黄斑水肿的真实生活经验。
Int Ophthalmol. 2019 Jul;39(7):1511-1522. doi: 10.1007/s10792-018-0970-7. Epub 2018 Jun 20.
7
Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabetes.降脂药物与美国糖尿病患者视网膜病变和眼科干预风险降低相关。
Am J Ophthalmol. 2019 Nov;207:378-384. doi: 10.1016/j.ajo.2019.05.029. Epub 2019 Jun 10.
8
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.玻璃体腔内抗血管内皮生长因子与假治疗预防糖尿病视网膜病变致盲性并发症的效果:方案 W 随机临床试验。
JAMA Ophthalmol. 2021 Jul 1;139(7):701-712. doi: 10.1001/jamaophthalmol.2021.0606.
9
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.全视网膜光凝与雷珠单抗治疗增生型糖尿病视网膜病变:与视力和水肿结局相关的因素。
Ophthalmology. 2018 Nov;125(11):1776-1783. doi: 10.1016/j.ophtha.2018.04.039. Epub 2018 Jul 3.
10
Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.雷珠单抗治疗对糖尿病视网膜病变严重程度和视网膜病变恶化的基线危险因素的长期影响。
Ophthalmology. 2015 Feb;122(2):367-74. doi: 10.1016/j.ophtha.2014.08.048. Epub 2014 Nov 18.

引用本文的文献

1
Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema.与玻璃体内注射康柏西普治疗糖尿病性黄斑水肿的临床反应相关的肾功能障碍
Int J Ophthalmol. 2025 Mar 18;18(3):454-461. doi: 10.18240/ijo.2025.03.12. eCollection 2025.
2
Association of hearing, vision, and dual sensory impairment and risk of Alzheimer's disease: a nested case-control study.听力、视力和双重感觉障碍与阿尔茨海默病风险的关联:一项巢式病例对照研究。
BMC Geriatr. 2024 Nov 11;24(1):929. doi: 10.1186/s12877-024-05514-z.
3
Global certification of visual impairment registries: A scoping review.
视力损害登记的全球认证:一项范围综述。
Acta Ophthalmol. 2025 Feb;103(1):7-15. doi: 10.1111/aos.16763. Epub 2024 Sep 28.